WO2002056867A2 - Extended release pharmaceutical compositions containing beta-lactam antibiotics - Google Patents
Extended release pharmaceutical compositions containing beta-lactam antibiotics Download PDFInfo
- Publication number
- WO2002056867A2 WO2002056867A2 PCT/IN2002/000009 IN0200009W WO02056867A2 WO 2002056867 A2 WO2002056867 A2 WO 2002056867A2 IN 0200009 W IN0200009 W IN 0200009W WO 02056867 A2 WO02056867 A2 WO 02056867A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extended release
- weight
- pharmaceutical composition
- release pharmaceutical
- lactam antibiotics
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
Definitions
- the invention disclosed is an oral pharmaceutical composition for extended release of active ingredient, at least one ⁇ -lactam antibiotic specifically intended for the release of drugs possessing a site-specific absorption upon oral administration, useful for maintaining the desired therapeutic concentration of active ingredient in blood for an extended time periods thus meeting the requirements for effective management of certain infectious diseases minimizing the dosing frequency and patient intervention.
- the invention also includes a process for preparation of the pharmaceutical composition.
- the oral pharmaceutical composition of the invention is a polymeric matrix containing at least one ⁇ -lactam antibiotic along with other excipients and additives, either in the form of a tablet or a capsule or a dry syrup for reconstitution at the time of administration.
- the relationship between pharmacokinetic and pharmacodynamic parameters depends on three elements: the pathogen, the host and specific antimicrobial agent.
- the Post-antibiotic effect of the drug is another pharmacodynamic parameter that has to be considered in determining the optimal dosage regimen.
- the present invention is based on our finding that invitro dissolution profile of an antibiotic from an extended release composition containing an antibiotic or its prodrugs, coated with release modulating polymer which maintains the integrity of the dosage form in varying pH conditions of gastrointestinal tract, compressed into tablets or filled into gelatin capsules or as a dry syrup for reconstitution, when administered orally to humans for the treatment of infectious diseases provides a therapeutic concentration over an extended period of time with better patient compliance.
- This provides preprogrammed, unattended delivery of drug at a rate and for a time period meeting to therapeutic need.
- Such drug delivery system minimizes patients intervention and maximizes compliance with the prescribed dose regimen.
- the present invention relates to a pharmaceutical composition in the form of an extended release oral drug delivery system comprising an active ingredient such as ⁇ -lactam antibiotic agent having a specific absorption site in gastrointestinal tract in combination with a polymeric material forming a matrix along with other pharmaceutically acceptable additives, wherein at least 25% of active antibiotic agent is released from said matrix within 0.5 to 1.0 hour after oral administration and a substantial amount of remaining active ingredient over an extended period, but within 2 to 5 hours after administration.
- This facilitates the complete absorption of the active ingredient before it crosses the "absorption window" where an active carrier mediated transport takes place across the g.i.t. membrane.
- the concept of present invention can be effectively applied to any pharmaceutical agent which has an "absorption window".
- the drug granules may consist of at least one ⁇ -lactam antibiotic along with other pharmaceutically acceptable additives, a release modulating polymer with plasticizer and anti- adherent.
- the pharmaceutical composition of the invention can be in the form of (a) tablet containing drug granules, diluents or fillers, lubricants (b) capsule containing drug granules, fillers, lubricants or (c) dry syrup containing granules admixed with additives such as sweetners, flavours etc, suitable for oral administration upon reconstitution.
- the main objective of the present invention is to provide a novel extended release pharmaceutical composition containing antibacterial substance selected particularly from ⁇ - lactam antibiotics which are useful for the treatment of infectious diseases.
- Another objective of the present invention is to provide a novel extended release pharmaceutical composition containing an antibiotic which is effective for a longer period of time when compared to the conventional immediate release pharmaceutical composition.
- Still another objective of the present invention is to provide a novel pharmaceutical composition which is therapeutically effective over an extended period of at least 10 -14 hours, providing initial dose of active substance for absorption immediately i.e. within 0.5 to 1.0 hour and to release substantial amount of the remaining active substance at a rate sufficient to maintain the drug concentration in therapeutically effective range for a desired period of time.
- the present invention provides a novel oral extended release pharmaceutical composition containing an antibiotic, useful for the treatment of infectious diseases comprising the drug in the form of a tablet or capsule or dry syrup for reconstitution made from the granules of drug coated with release modulating polymer composition.
- the formulation also contain necessary pharmaceutical additives.
- the invention also provides a process for the preparation of the above said pharmaceutical composition.
- an extended release pharmaceutical composition containing a ⁇ -lactam antibiotic capable of providing the required initial dose followed by extended release of the remaining drug where in the active substance is selected from penicillins or cephalosporins.
- an extended Pharmaceutical release composition wherein the said ⁇ -lactam antibiotic drug is selected from penicillins such penicillin V, penicillin G, amoxicillin, ampicillin, cloxacillin, oxacillin, nafcilin, and derivatives thereof or cephalosporins such as cefadroxil, cefixime,
- the amount of drug employed may range from 500.0 to 900. Omg more preferably 550.0 to 800.0 mg per gram of drug granules.
- the polymers used are selected from cellulose derivatives such as cellulose acetate phthalate, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, ethyl cellulose or methacrylic acid derivatives such as poly(methacrylic acid, methyl methacrylate) (1:1) and poly(methacrylic acid ethylacrylate) (1:1) (Eudragit L100 and Eudragit L100-55) and the like.
- the amount of polymer employed may range from about 20.0mg to about 400.0mg more preferably 25. Omg to 250.0mg per gram of drug granules.
- the plasticizer is selected from among phthalate derivatives such as diethyl phthalate, dipropyl phthalate, dioctyl phthalate, dibutyl phthalate, or glycol derivatives such as propylene glycol, polyethylene glycols of molecular weight ranging from 200 - 6000, or triethyl citrate or triacetin or a mixture thereof, the amount of which may range from about 10.0% to about 30.0% by weight of the polymer.
- the anti-adherents used are selected from talc, magnesium stearate, calcium carbonate, magnesium carbonate, the amount of which may range from about 10.0% to about 30.0% by weight of the polymer.
- the granular matrix is formulated as a unit dosage form of a tablet or a capsule or in the form of a dry syrup for reconstitution at the time of administration.
- the tablets and capsules contain pharmaceutical additives selected from diluents such as starch, lactose, microcrystalline cellulose, dicalcium phosphate or mixture thereof and lubricants such as talc, hydrogenated castor oil, magnesium stearate, stearic acid, calcium stearate, zinc stearate or a mixture thereof.
- the amount of diluents may range from about 20.0 to about 500.0 mg, more preferably 50.0 to 400.0mg per gram of drug granules.
- the amount of lubricant may range from about 5.0 to about 50.0mg more preferably 10.0 to 40.0mg per gram of drug granules.
- the dry syrup dosage units contain pharmaceutically acceptable additives selected from sweeteners such as sucrose, glucose, aspartame, sodium saccharin, N-methyl glycerrhezinate, fructose; flavours such as pineapple, strawberry, banana, vanilla, orange, mango, raspberry; colours such as titanium dioxide, erythrosine, brilliant blue, indigo carmine, tartrazine, ponceau 4R, sunset yellow, quinoline yellow, red oxide of iron, yellow oxide of iron;
- sweeteners such as sucrose, glucose, aspartame, sodium saccharin, N-methyl glycerrhezinate, fructose
- flavours such as pineapple, strawberry, banana, vanilla, orange, mango, raspberry
- colours such as titanium dioxide, erythrosine, brilliant blue, indigo carmine, tartrazine, ponceau 4R, sunset yellow, quinoline yellow, red oxide of iron, yellow oxide of iron;
- preservatives such as methyl paraben, propyl paraben and their sodium salts
- buffers and flavour enhancers such as citric acid, sodium citrate and the like
- antioxidants such as sodium sulphite, sodium bisulphite, sodium metabisulphite, sodium benzoate, butylated hydroxy toluene, butylated hydroxy anisole and the like.
- the invention also provides a process for the preparation of the above said composition, which comprises i) Preparation of granules comprising drug. ii) Coating of the granules with a polymer dissolved in a mixture of organic solvents along with a plasticizer and anti-adherent. iii) Formulating the granules into tablets or capsules or dry syrup for reconstitution with suitable pharmaceutical additives.
- the present invention provides a method for preparing the granules by dry granulation or wet granulation employing polymer solution in an organic solvent or blend of solvents.
- the granules are further coated with a release modulating polymeric composition in a blend of organic solvents such as acetone, ethyl alcohol, isopropyl alcohol, methylene chloride and the like.
- the granules are admixed with diluents and lubricants followed by either compression into tablets on a rotary compression machine or filled in to hard gelatin capsules on a capsule- filling machine.
- the dry syrup may be prepared by admixing the granules with sweeteners, flavours, colourants, preservatives, antioxidants and buffers and flavour enhancers.
- the dosage form described herein provides controlled drug entry into systemic circulation via gastrointestinal tract. It has advantages over conventional dosage forms for systemic therapy.
- the rationale for such dosage form is based on its capability of maintaining drug concentrations in blood within a range that selectively elicits desired therapeutic effects over an extended time period in comparison to conventional dosage forms.
- composition mg / g
- Hydroxypropyl methylcellulose was dissolved in a blend of isopropyl alcohol and acetone along with diethyl phthalate and dispersed talc in it.
- the compacted granules of ampicillin trihydrate were coated with the polymer composition and dried at 50°C.
- composition mg / g
- the ampicillin coated granules were mixed with ampicillin trihydrate granules, starch and microcrystalline cellulose powder and lubricated with talc and magnesium stearate. The lubricated granules were compressed into tablets on a rotary tablet press.
- Stage 1 Composition mg / g
- Poly(methacrylic acid, methyl methacrylate) was dissolved in a blend of isopropyl alcohol and acetone along with triethyl citrate and dispersed talc in it.
- the compacted granules of cefadroxil monohydrate were coated with the polymer composition and dried at 50°C.
- composition mg / g
- cefadroxil coated granules were mixed with cefadroxil granules, starch and microcrystalline cellulose powder and lubricated with magnesium stearate. The lubricated granules were compressed into tablets on a rotary tablet press. EXAMPLE -HI
- composition mg / g
- Cellulose acetate phthalate was dissolved in a blend of isopropyl alcohol and methylene chloride along with diethyl phthalate and dispersed talc in it.
- the compacted granules of cloxacillin sodium containing hydroxypropyl methylcellulose were coated with the polymer composition and dried at 50°C.
- composition mg / g
- the starch, dicalcium phosphate and microcrystalline cellulose powder were mixed and granulated with starch paste.
- the wet mass was passed through 14# and dried at 65°C.
- the cloxacillin coated granules were mixed with the above dry granules along with cloxacillin sodium granules and lubricated with magnesium stearate.
- the lubricated granules were filled into hard gelatin capsules on a capsule-filling machine.
- composition mg / g
- Sucrose was milled to a fine grade and mixed with other ingredients which are previously sifted through 30# and finally mixed with the cefuroxime granules. The dry mixture was filled in to unit dose packs.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention disclosed in this application relates to an extended release oral pharmaceutical composition containing at least one β-lactam anti-biotic intended for releasing the drug over an extended period upon administration. The pharmaceutical composition is useful for maintaining the desired the therapeutic concentration of active ingredient in blood for extended time periods thus meeting the requirements for effective management of infectious diseases. The pharmaceutical composition is either in the form of a tablet, capsule or dry syrup for reconstitution at the time of administration, releasing the active ingredient as initial dose and maintenance dose at a specific rate. The invention disclosed in this application also relates to a process for formulation of an extended release pharmaceutical composition containing β-lactam antibiotics.
Description
AN EXTENDED RELEASE PHARMACEUITCAL COMPOSITION CONTAINING β -LACTAM ANTIBIOTICS WITH IMPROVED THERAPEUTIC EFFICACY
The invention disclosed is an oral pharmaceutical composition for extended release of active ingredient, at least one β-lactam antibiotic specifically intended for the release of drugs possessing a site-specific absorption upon oral administration, useful for maintaining the desired therapeutic concentration of active ingredient in blood for an extended time periods thus meeting the requirements for effective management of certain infectious diseases minimizing the dosing frequency and patient intervention. The invention also includes a process for preparation of the pharmaceutical composition.
The oral pharmaceutical composition of the invention is a polymeric matrix containing at least one β-lactam antibiotic along with other excipients and additives, either in the form of a tablet or a capsule or a dry syrup for reconstitution at the time of administration.
The discovery of pencillins in the year 1929, by Alexander Flemming, has brought many changes in the concepts and the treatment of infectious diseases caused by bacteria and other microorganisms. Today a large number of antibiotic compounds have been developed for the treatment of infections caused by different microorganisms. Among the various types, β- lactams occupy a recognizable place. These β-lactams are active against wide variety of infections, with ideal therapeutic index, but suffers from very short biological half-life, requiring frequent administration to elicit desired therapeutic response. Further their site- specific gastrointestinal absorption may limit the therapeutic applications. Furthermore, it is well established that the contact of various β-lactams causes damage to the intestinal flora (Ref.: (a) Nord and Edlund., J. Chemother. 2,218,1990. (b) Pien FD., Antimicrobial Agents and Chemother.;24,856,1983. (c) Fleisher et al., Antimicrobial Agents and Chemother., 24,679,1983.). The poor bioavailability and adverse effects can be over come by using prodrug of the respective compounds. However prodrug approach also not yielded complete bioavailability.
A recent study (Drusano and Craig, J. Chemother., 9,38,1998) revealed that the antibiotic activity of β-lactams is solely dependent on the time of exposure to microorganisms, above its minimum inhibitory concentration (MIC) rather than the peak plasma/serum concentration. This may be obtained by continuous infusion, which may requires hospitalization and continuous monitoring.
Hence the selection of suitable alternate mode of drug administration is of primary goal since the efficacy of the drug greatly depends on the time duration above minimum inhibitory concentration (MIC). The selection should be based upon the pharmacokinetic and pharmacodynamic parameters.
In case of antibiotics the relationship between pharmacokinetic and pharmacodynamic parameters depends on three elements: the pathogen, the host and specific antimicrobial agent. The Post-antibiotic effect of the drug is another pharmacodynamic parameter that has to be considered in determining the optimal dosage regimen.
Based on the above an oral extended release preparation for β-lactam antibiotics that would maintain low but effective concentrations for a prolonged period would be the suitable mode of administration for prolonged therapy.
Arancibia et al. [Int.J.Clin. Pharmacol. Ther. Toxicol, 25, 97, (1987)] studied the bioavailability of amoxicillin after oral administration of controlled-release tablets, and observed that in any case, no drug was detectable after 8 hours and therefore concluded this formulation had no advantage over conventional formulation.
Uchida et. al. [Chem. Pharm. Bull., 37, 3416, (1989)] described a method for the preparation of amoxicillin microcapsules using ethyl cellulose. These microcapsules exhibited a controlled release pattern when administered to beagle dogs. However, such effect could be foreseen, since the gastric pH of the dogs which were tested is considerably higher than human gastric pH (pH of about 6 in beagle dogs, compared to pH of about 2 in humans). The preliminary studies on amoxicillin reveals that it is much less soluble at pH 6 than at pH 2 [Tsuji et.al., J. Pharm. Sci., 67, 1059 (1978)] One would expect to obtain a very quick
release of the drug from the same microcapsules if administered to humans. Hence these may not be considered to relate with the human studies.
Martin et al. (US Patent No. 5,851,550) studied the influence of co-administration of clavunic acid with amoxicillin and found that the bioavailability and subsequently therapeutic response was improved compared to conventional dosage form upon oral administration. However, the manufacture of products containing clavunic acid required controlled environmental conditions which may increase the manufacturing costs.
Hilton and Deasy [Int. J. Pharm., 86, 79, (1992)] described a floating tablet of amoxicillin trihydrate. This tablet remained buoyant for 6 hours and had satisfactory in vitro sustained release but lack of bioavailability compared to that of conventional capsule at a dose of 500mg.
Hilton and Deasy [J. Pharm. Sci., 82, 737, (1993)] also described about controlled release tablet of amoxicillin containing hydroxypropyl methylcellulose acetate succinate as a matrix carrier. This polymer retarded the release of amoxicillin in gastric pH but could not enhance its release in the duodenum, proximal parts of Jejumum of small intestine where maximum absorption is likely to take place. Further, single dose in vivo studies in fasting subjects showed that the tablets had a relative bioavailability of only 64.4%, probably because the poorer absorption of drug from the distal jejunum and ileum than from the duodenum and proximal jejunum.
Katzhendler (PCT application No. WO98/122091) disclosed a pharmaceutical composition for the controlled release of β-lactam antibiotics employing various types of cellulose and acrylic polymer derivatives. According to this invention, an initial release of 50.0 % drug in 3-4 hours after administration of dosage form and the drug release continued up to 8 hours. Further the author stated that the free drug is not in contact with the intestinal flora as it is embedded in a matrix and hence the drug is not degraded before it is being absorbed. These statements are contradicting with each other. As there is no carrier mediated mechanism for the absorption of β-lactams beyond the distal part of jejunum, the drug may not be absorbed completely, which may lead to reduced bioavailability and damage of gastrointestinal flora due to continuous presence of free drug in intestinal tract.
In view of the above we aimed to develop an oral extended-release preparations of different drugs belonging to β-lactam antibiotics group such as pencillins and cephalosporins to optimize therapeutic response of these drugs. A promising approach for achieving this would be optimization of the drug release such that total dose from the dosage form is released within the time of transit through absorption window. The advantages of such preparations are
(a) improving patient compliance by minimizing the frequency of drug administration to once or twice a day, and (b) avoiding the damage to the gastrointestinal flora.
The present invention is based on our finding that invitro dissolution profile of an antibiotic from an extended release composition containing an antibiotic or its prodrugs, coated with release modulating polymer which maintains the integrity of the dosage form in varying pH conditions of gastrointestinal tract, compressed into tablets or filled into gelatin capsules or as a dry syrup for reconstitution, when administered orally to humans for the treatment of infectious diseases provides a therapeutic concentration over an extended period of time with better patient compliance. This provides preprogrammed, unattended delivery of drug at a rate and for a time period meeting to therapeutic need. Such drug delivery system minimizes patients intervention and maximizes compliance with the prescribed dose regimen.
The present invention relates to a pharmaceutical composition in the form of an extended release oral drug delivery system comprising an active ingredient such as β-lactam antibiotic agent having a specific absorption site in gastrointestinal tract in combination with a polymeric material forming a matrix along with other pharmaceutically acceptable additives, wherein at least 25% of active antibiotic agent is released from said matrix within 0.5 to 1.0 hour after oral administration and a substantial amount of remaining active ingredient over an extended period, but within 2 to 5 hours after administration. This facilitates the complete absorption of the active ingredient before it crosses the "absorption window" where an active carrier mediated transport takes place across the g.i.t. membrane. The concept of present invention can be effectively applied to any pharmaceutical agent which has an "absorption window".
The drug granules may consist of at least one β-lactam antibiotic along with other pharmaceutically acceptable additives, a release modulating polymer with plasticizer and anti- adherent. The pharmaceutical composition of the invention can be in the form of (a) tablet containing drug granules, diluents or fillers, lubricants (b) capsule containing drug granules, fillers, lubricants or (c) dry syrup containing granules admixed with additives such as sweetners, flavours etc, suitable for oral administration upon reconstitution.
Accordingly the main objective of the present invention is to provide a novel extended release pharmaceutical composition containing antibacterial substance selected particularly from β- lactam antibiotics which are useful for the treatment of infectious diseases.
Another objective of the present invention is to provide a novel extended release pharmaceutical composition containing an antibiotic which is effective for a longer period of time when compared to the conventional immediate release pharmaceutical composition.
Still another objective of the present invention is to provide a novel pharmaceutical composition which is therapeutically effective over an extended period of at least 10 -14 hours, providing initial dose of active substance for absorption immediately i.e. within 0.5 to 1.0 hour and to release substantial amount of the remaining active substance at a rate sufficient to maintain the drug concentration in therapeutically effective range for a desired period of time.
Accordingly, the present invention provides a novel oral extended release pharmaceutical composition containing an antibiotic, useful for the treatment of infectious diseases comprising the drug in the form of a tablet or capsule or dry syrup for reconstitution made from the granules of drug coated with release modulating polymer composition. The formulation also contain necessary pharmaceutical additives.
According to another embodiment the invention also provides a process for the preparation of the above said pharmaceutical composition.
According to the present invention, an extended release pharmaceutical composition containing a β-lactam antibiotic capable of providing the required initial dose followed by
extended release of the remaining drug where in the active substance is selected from penicillins or cephalosporins.
An extended Pharmaceutical release composition wherein the said β-lactam antibiotic drug is selected from penicillins such penicillin V, penicillin G, amoxicillin, ampicillin, cloxacillin, oxacillin, nafcilin, and derivatives thereof or cephalosporins such as cefadroxil, cefixime,
cefuroxime axetil, cefadroxil, cefaclor and derivatives thereof. The amount of drug employed may range from 500.0 to 900. Omg more preferably 550.0 to 800.0 mg per gram of drug granules.
According to the invention the polymers used are selected from cellulose derivatives such as cellulose acetate phthalate, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, ethyl cellulose or methacrylic acid derivatives such as poly(methacrylic acid, methyl methacrylate) (1:1) and poly(methacrylic acid ethylacrylate) (1:1) (Eudragit L100 and Eudragit L100-55) and the like. The amount of polymer employed may range from about 20.0mg to about 400.0mg more preferably 25. Omg to 250.0mg per gram of drug granules.
The plasticizer is selected from among phthalate derivatives such as diethyl phthalate, dipropyl phthalate, dioctyl phthalate, dibutyl phthalate, or glycol derivatives such as propylene glycol, polyethylene glycols of molecular weight ranging from 200 - 6000, or triethyl citrate or triacetin or a mixture thereof, the amount of which may range from about 10.0% to about 30.0% by weight of the polymer. The anti-adherents used are selected from talc, magnesium stearate, calcium carbonate, magnesium carbonate, the amount of which may range from about 10.0% to about 30.0% by weight of the polymer.
The granular matrix is formulated as a unit dosage form of a tablet or a capsule or in the form of a dry syrup for reconstitution at the time of administration. The tablets and capsules contain pharmaceutical additives selected from diluents such as starch, lactose, microcrystalline cellulose, dicalcium phosphate or mixture thereof and lubricants such as talc, hydrogenated castor oil, magnesium stearate, stearic acid, calcium stearate, zinc stearate or a mixture thereof. The amount of diluents may range from about 20.0 to about 500.0 mg, more
preferably 50.0 to 400.0mg per gram of drug granules. The amount of lubricant may range from about 5.0 to about 50.0mg more preferably 10.0 to 40.0mg per gram of drug granules.
The dry syrup dosage units contain pharmaceutically acceptable additives selected from sweeteners such as sucrose, glucose, aspartame, sodium saccharin, N-methyl glycerrhezinate, fructose; flavours such as pineapple, strawberry, banana, vanilla, orange, mango, raspberry; colours such as titanium dioxide, erythrosine, brilliant blue, indigo carmine, tartrazine, ponceau 4R, sunset yellow, quinoline yellow, red oxide of iron, yellow oxide of iron;
preservatives such as methyl paraben, propyl paraben and their sodium salts; buffers and flavour enhancers such as citric acid, sodium citrate and the like; antioxidants such as sodium sulphite, sodium bisulphite, sodium metabisulphite, sodium benzoate, butylated hydroxy toluene, butylated hydroxy anisole and the like.
According to another embodiment the invention also provides a process for the preparation of the above said composition, which comprises i) Preparation of granules comprising drug. ii) Coating of the granules with a polymer dissolved in a mixture of organic solvents along with a plasticizer and anti-adherent. iii) Formulating the granules into tablets or capsules or dry syrup for reconstitution with suitable pharmaceutical additives.
According to the above the present invention provides a method for preparing the granules by dry granulation or wet granulation employing polymer solution in an organic solvent or blend of solvents. The granules are further coated with a release modulating polymeric composition in a blend of organic solvents such as acetone, ethyl alcohol, isopropyl alcohol, methylene chloride and the like.
The granules are admixed with diluents and lubricants followed by either compression into tablets on a rotary compression machine or filled in to hard gelatin capsules on a capsule- filling machine. The dry syrup may be prepared by admixing the granules with sweeteners, flavours, colourants, preservatives, antioxidants and buffers and flavour enhancers.
The controlled yet complete release of antibiotic prior to crossing the absorption window will have maximum bioavailability with enhanced therapeutic response, minimizes local side effects, reduced dosing frequency and improved patient compliance.
The dosage form described herein provides controlled drug entry into systemic circulation via gastrointestinal tract. It has advantages over conventional dosage forms for systemic therapy. The rationale for such dosage form is based on its capability of maintaining drug concentrations in blood within a range that selectively elicits desired therapeutic effects over an extended time period in comparison to conventional dosage forms.
Advantages.
1) Prolonged therapeutic response when compared to conventional oral formulations. 2) Reduce the dosing frequency.
3) Improves patient compliance.
4) Avoids intestinal flora damage.
The invention is described in detail in the examples given below which are provided by way of illustration only and therefore should not be construed to limit the scope of the invention.
EXAMPLE -I
Stage 1
Composition: mg / g
Ampicillin Trihydrate 900.00
Hydroxypropyl methylcellulose phthalate 60.00
Diethylphthalate 18.00
Talc 22.00
Isopropyl alcohol qs.
Acetone qs.
Hydroxypropyl methylcellulose was dissolved in a blend of isopropyl alcohol and acetone along with diethyl phthalate and dispersed talc in it. The compacted granules of ampicillin trihydrate were coated with the polymer composition and dried at 50°C.
Stage 2
Composition: mg / g
Ampicillin coated granules 560.00
Ampicillin granules 145.00
Starch 180.00
Microcrystalline cellulose powder 95.00
Talc 10.00
Magnesium stearate 10.00
The ampicillin coated granules were mixed with ampicillin trihydrate granules, starch and microcrystalline cellulose powder and lubricated with talc and magnesium stearate. The lubricated granules were compressed into tablets on a rotary tablet press.
EXAMPLE -π
Stage 1 Composition: mg / g
Cefadroxil Monohydrate 925.00 Poly(methacrylic acid, methyl methacrylate) 45.00
Triethyl citrate 14.00
Talc 16.00 Isopropyl alcohol qs.
Acetone qs.
Poly(methacrylic acid, methyl methacrylate) was dissolved in a blend of isopropyl alcohol and acetone along with triethyl citrate and dispersed talc in it. The compacted granules of cefadroxil monohydrate were coated with the polymer composition and dried at 50°C.
Stage 2
Composition: mg / g
Cefadroxil coated granules 520.00
Cefadroxil granules 140.00
Starch 180.00
Microcrystalline cellulose powder 140.00
Magnesium stearate 20.00
The cefadroxil coated granules were mixed with cefadroxil granules, starch and microcrystalline cellulose powder and lubricated with magnesium stearate. The lubricated granules were compressed into tablets on a rotary tablet press.
EXAMPLE -HI
Stage 1
Composition: mg / g
Cloxacillin Sodium 800.00
Cellulose acetate phthalate 70.00
Hydroxy propyl methylcellulose 90.0 Diethylphthalate 19.50
Talc 24.00
Isopropyl alcohol qs.
Methylene chloride qs.
Cellulose acetate phthalate was dissolved in a blend of isopropyl alcohol and methylene chloride along with diethyl phthalate and dispersed talc in it. The compacted granules of cloxacillin sodium containing hydroxypropyl methylcellulose were coated with the polymer composition and dried at 50°C.
Stage 2
Composition: mg / g
Cloxacillin coated granules 540.00
Cloxacillin Sodium granules 160.00 Starch 115.00
Dicalcium phosphate 70.00
Microcrystalline cellulose powder 95.00
Magnesium stearate 20.00
The starch, dicalcium phosphate and microcrystalline cellulose powder were mixed and granulated with starch paste. The wet mass was passed through 14# and dried at 65°C. The cloxacillin coated granules were mixed with the above dry granules along with cloxacillin sodium granules and lubricated with magnesium stearate. The lubricated granules were filled into hard gelatin capsules on a capsule-filling machine.
EXAMPLE - IV
Stage 1
Composition: mg / g
Cefuroxime Axetil 920.00
Hydroxypropyl methylcellulose phthalate 54.00
Diethylphthalate 10.80
Talc 15.20
Isopropyl alcohol qs.
Acetone qs.
Hydroxypropyl methylcellulose was dissolved in a blend of isopropyl alcohol and acetone along with diethyl phthalate and dispersed the talc in it. The compacted granules of cefuroxime axetil were coated with the polymer composition and dried at 50°C. Stage 2
Composition: mg / 15ml
Cefuroxime coated granules 450.00
Cefuroxime axetil granules 150.00
Sodium CMC 40.50 Sodium citrate 16.00
Sodium benzoate 39.00
Quinoline Yellow 1.00
Sunset Yellow 1.50
Pineapple dry flavour 10.00 Orange DC 116 flavour 6.00
Straberry DC 109 flavour 2.60
Vanilla DC 110 flavour 2.80
Colloidal silicon dioxide 25.00
Sucrose 2500.00
Sucrose was milled to a fine grade and mixed with other ingredients which are previously sifted through 30# and finally mixed with the cefuroxime granules. The dry mixture was filled in to unit dose packs.
Claims
CLAIMS:
01) An extended pharmaceutical release composition containing at least one β-lactam antibiotic in the form of granular matrix of about 50.0% to about 90.0 % by weight, about
2.0% to about 40% of polymer by weight, 1.0% to about 20.0% of pharmaceutically acceptable inactive ingredients, the granular matrix is further coated with polymer composition comprising of a film forming polymer and other coating aids, wherein about 25%o of the said active ingredient is released after lhr of oral administration and the remainder of active ingredient is release at a controlled rate before crossing the absorption window.
02) An extended release pharmaceutical composition according to claim 1 wherein the said β-lactam antibiotic drug is selected from penicillins such penicillin V, penicillin G, amoxicillin, ampicillin, cloxacillin, oxacillin, nafcilin, and derivatives thereof or cephalosporins such as cefadroxil, cefixime, cefuroxime axetil, cefadroxil, cefaclor and derivatives thereof.
03) An extended release pharmaceutical composition of β-lactam antibiotics according to claim 1 which provides therapeutically effective concentrations of drug in blood over an extended period of 8 to 12 hours.
04) An extended release pharmaceutical composition of β-lactam antibiotics according to claim 1 wherein the granular matrix is coated with a composition from about 1.0% to about 20.0% of granular matrix weight and the polymeric composition is comprised of from about 40.0% to about 80.0% by weight of polymer and from about 10.0% to about 30.0% by weight of plasticizer and from about 10.0% to about 30.0% by weight of anti adherent.
05) An extended release pharmaceutical composition of β-lactam antibiotics according to claim 1 wherein the polymer used in preparing the granular matrix and film is selected from cellulose derivatives such as cellulose acetate phthalate, hydroxypropyl methylcellulose and hydroxypropyl methylcellulose phthalate and the like or methacrylic acid derivatives such as poly(methacrylic acid, methyl methacrylate) (1:1) and poly(methacrylic acid, ethylacrylate) (1:1) and the like, the amount of which may range from 2% to about 40% by weight of granules.
06) An extended release pharmaceutical composition of β-lactam antibiotics according to claim 1 wherein the plasticizer used in the film coating of granular matrix is selected from diethyl phthalate, dipropyl phthalate, dioctyl phthalate, dibutyl phthalate, propylene glycol, polyethylene glycols of molecular weight ranging from 200 - 6000, triethyl citrate, triacetin or a mixture thereof, the amount of which may range from about 10.0% to about 30.0% by weight of the polymer. The antiadherants used are selected from talc, magnesium stearate, calcium carbonate, magnesium carbonate, the amount of which may range from about 10.0% to about 30.0% by weight of the polymer.
07) An extended release pharmaceutical composition of β-lactam antibiotics according to claim 1 wherein the granular matrix is formulated as a unit dosage form of a tablet or a capsule or in the form of a dry syrup for reconstitution at the time of administration.
08) An extended release pharmaceutical composition of β-lactam antibiotics according to claim 1 and 8 wherein the unit dosage form of tablet and capsule contains further pharmaceutically acceptable additives selected from diluents and disintegrants such as starch, lactose, microcrystalline cellulose and dicalcium phosphate from about 5.0% to about 50.0% by weight and lubricants selected such as talc, hydrogenated castor oil, magnesium stearate, stearic acid, calcium steareate, zinc stearate, from about 0.5% to about 4.0% by weight
09) An extended release pharmaceutical formulation of β-lactam antibiotics according to claim 1 and 8 wherein the dry syrup dosage units contain further pharmaceutically acceptable additives selected from sweeteners such as sucrose, glucose, aspartame, sodium saccharin, N-methyl glycerrhezinate, fructose; flavours such as pineapple, strawberry, banana, vanilla, orange, mango, raspberry; colours such as titanium dioxide, erythrosine, brillient blue, indigo carmine, tartrazine, ponceau 4R, sunset yellow, quinoline yellow, red oxide of iron, yellow oxide of iron; preservatives such as methyl paraben, propyl paraben and their sodium salts; buffers and flavour enhancers such as citric acid, sodium citrate and the like; antioxidants such as sodium sulphite, sodium bisulphite, sodium metabisulphite, sodium benzoate, butylated hydroxy toluene, butylated hydroxy anisole and the like.
10) An extended release pharmaceutical formulation of β-lactam antibiotics according to claim 1 wherein the process for preparing the same, which comprises i) Preparation of granules comprising drug. ii) Coating of the granules with a polymer dissolved in a mixture of organic solvents along with a plasticizer and anti-adherent. iii) Formulating the granules into tablets or capsules or dry syrup for reconstitution with suitable pharmaceutical additives.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002435305A CA2435305A1 (en) | 2001-01-18 | 2002-01-18 | Extended release pharmaceutical compositions containing beta-lactam antibiotics |
| JP2002557375A JP2004520358A (en) | 2001-01-18 | 2002-01-18 | Sustained-release pharmaceutical compositions containing beta-lactam antibiotics with improved therapeutic efficacy |
| EP02701537A EP1353651A2 (en) | 2001-01-18 | 2002-01-18 | Extended release pharmaceutical compositions containing beta-lactam antibiotics |
| AU2002234868A AU2002234868A1 (en) | 2001-01-18 | 2002-01-18 | Extended release pharmaceutical compositions containing beta-lactam antibiotics |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN58/MAS/2001 | 2001-01-18 | ||
| IN58CH2001 | 2001-01-18 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2002056867A2 true WO2002056867A2 (en) | 2002-07-25 |
| WO2002056867A3 WO2002056867A3 (en) | 2003-03-06 |
Family
ID=11096990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IN2002/000009 Ceased WO2002056867A2 (en) | 2001-01-18 | 2002-01-18 | Extended release pharmaceutical compositions containing beta-lactam antibiotics |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1353651A2 (en) |
| JP (1) | JP2004520358A (en) |
| CA (1) | CA2435305A1 (en) |
| WO (1) | WO2002056867A2 (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2843880A1 (en) * | 2002-09-02 | 2004-03-05 | Flamel Tech Sa | Oral administered aqueous suspension of microencapsulated amoxicillin, having specific polymer-based, release-controlling film coating ensuring consistent release profile after storage |
| FR2872044A1 (en) * | 2004-06-28 | 2005-12-30 | Flamel Technologies Sa | PHARMACEUTICAL FORMULATION BASED ON ANTIBIOTICS IN THE MICROCAPSULAR FORM |
| EP1855647A4 (en) * | 2005-03-04 | 2010-11-17 | Intelgenx Corp | Delayed release pharmaceutical oral dosage form and method of making same |
| CN109260220A (en) * | 2018-11-28 | 2019-01-25 | 重庆华森制药股份有限公司 | A kind of preparation method of oyster shell calcium particle |
| CN113440530A (en) * | 2021-07-08 | 2021-09-28 | 广州白云山医药集团股份有限公司白云山制药总厂 | Cefixime medicament and preparation method thereof |
| CN113908133A (en) * | 2021-11-29 | 2022-01-11 | 河南省儿童医院郑州儿童医院 | Cefixime sustained-release tablet and preparation method thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114939113A (en) * | 2022-06-01 | 2022-08-26 | 澳美制药(苏州)有限公司 | Penicillin V potassium tablet and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS601128A (en) * | 1983-06-15 | 1985-01-07 | Shionogi & Co Ltd | Long-acting cefaclor preparation |
-
2002
- 2002-01-18 JP JP2002557375A patent/JP2004520358A/en not_active Withdrawn
- 2002-01-18 EP EP02701537A patent/EP1353651A2/en not_active Withdrawn
- 2002-01-18 WO PCT/IN2002/000009 patent/WO2002056867A2/en not_active Ceased
- 2002-01-18 CA CA002435305A patent/CA2435305A1/en not_active Abandoned
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2843880A1 (en) * | 2002-09-02 | 2004-03-05 | Flamel Tech Sa | Oral administered aqueous suspension of microencapsulated amoxicillin, having specific polymer-based, release-controlling film coating ensuring consistent release profile after storage |
| FR2872044A1 (en) * | 2004-06-28 | 2005-12-30 | Flamel Technologies Sa | PHARMACEUTICAL FORMULATION BASED ON ANTIBIOTICS IN THE MICROCAPSULAR FORM |
| WO2006010868A1 (en) * | 2004-06-28 | 2006-02-02 | Flamel Technologies | Pharmaceutical formulation based on antibiotic in microcapsule form |
| EP1855647A4 (en) * | 2005-03-04 | 2010-11-17 | Intelgenx Corp | Delayed release pharmaceutical oral dosage form and method of making same |
| CN109260220A (en) * | 2018-11-28 | 2019-01-25 | 重庆华森制药股份有限公司 | A kind of preparation method of oyster shell calcium particle |
| CN113440530A (en) * | 2021-07-08 | 2021-09-28 | 广州白云山医药集团股份有限公司白云山制药总厂 | Cefixime medicament and preparation method thereof |
| CN113440530B (en) * | 2021-07-08 | 2023-08-08 | 广州白云山医药集团股份有限公司白云山制药总厂 | Cefixime medicine and preparation method thereof |
| CN113908133A (en) * | 2021-11-29 | 2022-01-11 | 河南省儿童医院郑州儿童医院 | Cefixime sustained-release tablet and preparation method thereof |
| CN113908133B (en) * | 2021-11-29 | 2023-11-03 | 河南省儿童医院郑州儿童医院 | Cefixime sustained release tablet and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1353651A2 (en) | 2003-10-22 |
| WO2002056867A3 (en) | 2003-03-06 |
| JP2004520358A (en) | 2004-07-08 |
| CA2435305A1 (en) | 2002-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10285944B2 (en) | Gastroresistant pharmaceutical formulations containing rifaximin | |
| JP3699122B2 (en) | New oral pharmaceutical use form | |
| US7029701B2 (en) | Composition for the treatment and prevention of ischemic events | |
| US6767557B2 (en) | Taste masked pharmaceutical compositions | |
| US20110020408A1 (en) | multilayered modified release formulation comprising amoxicillin and clavulanate | |
| MXPA96004354A (en) | New form of pharmaceutical dosage or | |
| US20090111788A1 (en) | Antibiotic compositions of modified release and process of production thereof | |
| US20220062188A1 (en) | All-in-one fixed-dose combination for treating helicobacter pylori infection | |
| AU5880200A (en) | Taste masked pharmaceutical liquid formulations | |
| US20060110445A1 (en) | Dispersible tablet for oral administration | |
| WO2002056867A2 (en) | Extended release pharmaceutical compositions containing beta-lactam antibiotics | |
| JP2008504352A (en) | Formulations containing antibiotics in the form of microcapsules | |
| WO2004000281A1 (en) | Rapidly disintegrating tablet | |
| WO2011093829A1 (en) | Effervescent formulations comprising cefixime and clavulanic acid as active agents | |
| US20090088415A1 (en) | Controlled release pharmaceutical compositions | |
| EP2515905A1 (en) | Pharmaceutical formulations comprising a third generation cephalosporin and clavulanic acid | |
| GR1008992B (en) | Oral pharmaceutical composition in the form of granules comprising metronidazole or derivatives thereofand a taste-masking agent | |
| KR100475260B1 (en) | Granulate for the preparation of fast-disintegrating and fast-dissolvingcompositions containing a high amount of drug | |
| TR201511982A2 (en) | Antibacterial formulations | |
| US20110160156A1 (en) | Pharmaceutical Composition for the Eradication of Helicobacter Pylori and Preparation Method Thereof | |
| KR100523082B1 (en) | Taste masking pharmaceutical composition for oral administration | |
| EP1785135A1 (en) | New stabilized galenic formulations comprising lansoprazole and their preparation | |
| KR20040098907A (en) | EXTENDED RELEASE PHARMACEUTICAL FORMULATION CONTAINING A β-LACTAM ANTIBIOTIC AND CLAVULANIC ACID | |
| MXPA06007781A (en) | Controlled release pharmaceutical compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2002557375 Country of ref document: JP Ref document number: 2435305 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2002701537 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 2002701537 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 2002701537 Country of ref document: EP |